Cargando…

Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study

BACKGROUND: Infiltrating lobular carcinoma (ILC) is the second most common type of invasive breast cancers and it has been reported to have some unique biologic and epidemiologic characteristics. METHODS: Clinicopathological features of 95 patients with ILC, their relapse free survival (RFS) and ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ju-Hyun, Park, Seho, Park, Hyung Seok, Park, Byeong-Woo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873339/
https://www.ncbi.nlm.nih.gov/pubmed/20423478
http://dx.doi.org/10.1186/1477-7819-8-34
_version_ 1782181316851138560
author Lee, Ju-Hyun
Park, Seho
Park, Hyung Seok
Park, Byeong-Woo
author_facet Lee, Ju-Hyun
Park, Seho
Park, Hyung Seok
Park, Byeong-Woo
author_sort Lee, Ju-Hyun
collection PubMed
description BACKGROUND: Infiltrating lobular carcinoma (ILC) is the second most common type of invasive breast cancers and it has been reported to have some unique biologic and epidemiologic characteristics. METHODS: Clinicopathological features of 95 patients with ILC, their relapse free survival (RFS) and overall survival (OS) were retrospectively investigated and compared with those of 3,621 patients with infiltrating ductal carcinoma-not otherwise specified (IDC-NOS) between January 1984 and December 2005. RESULTS: ILC constitutes 2.3% of all invasive breast cancers. There were no difference between the ILC and the IDC-NOS groups regarding age at diagnosis, tumor size, nodal status, and treatment modalities except hormone therapy. The ILC group showed more estrogen receptor expression, less HER-2 expression and higher bilaterality. RFS and OS of the ILC patients were similar to those of the IDC. IDC-NOS metastasized more frequently to the lung and bone, whereas, ILC to the bone and ovary. CONCLUSIONS: The incidence of ILC was relatively low in Korean breast cancer patients. Comparing to IDC-NOS ILC showed some different features such as higher estrogen receptor expression, less HER-2 expression, higher bilaterality and preferred metastatic sites of bone and ovary. Contralateral cancers and bone and ovary evaluation should be considered when monitoring ILC patients.
format Text
id pubmed-2873339
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28733392010-05-20 Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study Lee, Ju-Hyun Park, Seho Park, Hyung Seok Park, Byeong-Woo World J Surg Oncol Research BACKGROUND: Infiltrating lobular carcinoma (ILC) is the second most common type of invasive breast cancers and it has been reported to have some unique biologic and epidemiologic characteristics. METHODS: Clinicopathological features of 95 patients with ILC, their relapse free survival (RFS) and overall survival (OS) were retrospectively investigated and compared with those of 3,621 patients with infiltrating ductal carcinoma-not otherwise specified (IDC-NOS) between January 1984 and December 2005. RESULTS: ILC constitutes 2.3% of all invasive breast cancers. There were no difference between the ILC and the IDC-NOS groups regarding age at diagnosis, tumor size, nodal status, and treatment modalities except hormone therapy. The ILC group showed more estrogen receptor expression, less HER-2 expression and higher bilaterality. RFS and OS of the ILC patients were similar to those of the IDC. IDC-NOS metastasized more frequently to the lung and bone, whereas, ILC to the bone and ovary. CONCLUSIONS: The incidence of ILC was relatively low in Korean breast cancer patients. Comparing to IDC-NOS ILC showed some different features such as higher estrogen receptor expression, less HER-2 expression, higher bilaterality and preferred metastatic sites of bone and ovary. Contralateral cancers and bone and ovary evaluation should be considered when monitoring ILC patients. BioMed Central 2010-04-27 /pmc/articles/PMC2873339/ /pubmed/20423478 http://dx.doi.org/10.1186/1477-7819-8-34 Text en Copyright ©2010 Lee et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Lee, Ju-Hyun
Park, Seho
Park, Hyung Seok
Park, Byeong-Woo
Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study
title Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study
title_full Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study
title_fullStr Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study
title_full_unstemmed Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study
title_short Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study
title_sort clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873339/
https://www.ncbi.nlm.nih.gov/pubmed/20423478
http://dx.doi.org/10.1186/1477-7819-8-34
work_keys_str_mv AT leejuhyun clinicopathologicalfeaturesofinfiltratinglobularcarcinomascomparingwithinfiltratingductalcarcinomasacasecontrolstudy
AT parkseho clinicopathologicalfeaturesofinfiltratinglobularcarcinomascomparingwithinfiltratingductalcarcinomasacasecontrolstudy
AT parkhyungseok clinicopathologicalfeaturesofinfiltratinglobularcarcinomascomparingwithinfiltratingductalcarcinomasacasecontrolstudy
AT parkbyeongwoo clinicopathologicalfeaturesofinfiltratinglobularcarcinomascomparingwithinfiltratingductalcarcinomasacasecontrolstudy